Systemic chemotherapy and survival in patients with metastatic low‐grade appendiceal mucinous adenocarcinoma

Pamela Lu(Brigham and Women's Hospital), Nelya Melnitchouk(Brigham and Women's Hospital), Jeffrey A. Meyerhardt(CancerCare), Ronald Bleday, Garrett M. Nash(Memorial Sloan Kettering Cancer Center), Galyna Shabat(Brigham and Women's Hospital), Adam C. Fields(Brigham and Women's Hospital), Jennifer S. Davids(Boston University), Joel E. Goldberg(Brigham and Women's Hospital)
Journal of Surgical Oncology
June 24, 2019
10.1002/jso.25599
Cited by 41

Related Papers

<i>Fusobacterium nucleatum</i>in colorectal carcinoma tissue and patient prognosis
|Gut|2015|1.1k
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
|Cell Reports|2016|936
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer
|JAMA|2017|891
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|846